A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Chandra, J., Woo, W. P., Finlayson, N., Liu, H. Y., McGrath, M., Ladwa, R., Brauer, M., Xu, Y., Hanson, S., Panizza, B., Frazer, I. H. and Porceddu, S. V.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002)…

Read More

Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma

Fedorova, L., Mudry, P., Pilatova, K., Selingerova, I., Merhautova, J., Rehak, Z., Valik, D., Hlavackova, E., Cerna, D., Faberova, L., Mazanek, P., Pavelka, Z., Demlova, R., Sterba, J., Zdrazilova-Dubska, L.  Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma.  Frontiers in Oncology. 2019; 9.  doi:10.3389/fonc.2019.01169

Read More